Introduction
Urinary infections with Candida albicans are not common (Guze and Haley, 1958; Seneca and Peer, 1965 ) but can be difficult to eradicate, especially in the presence of a physiological or anatomical abnormality. Until recently the only available systemic antifungal agent was amphotericin B, which is only poorly excreted in the urine (Louria, 1958) . Local therapy by irrigation with amphotericin B has been used (Goldman et al., 1960; Blum, 1966) but may not be successful and requires the presence of indwelling ureteric catheters or ureterostomies to ensure treatment of the upper part of the tract.
5-Fluorocytosine is an antimetabolite of the pyrimidine base cytosine showing a high degree of activity against C. albicans (Grunberg et al., 1964 (Grunberg et al., , 1967 but with relatively litthe reported toxicity in man (Koechlin et al., 1966; Grunberg et al., 1967; Tassel and Madoff, 1968; Utz et al., 1968) . Pharmacological studies have shown that, in man, it is not detectably metabolized and is mostly excreted in the urine in an unchanged form (Koechlin et al., 1966) . This suggests that high urinary levels of 5-fluorocytosine may be obtained with moderate dosage, even when some degree of renal failure is present, and that 5-fluorocytosine may therefore be useful for treating candida urinary infections.
In this paper we describe the treatment of two patients with urinary candidiasis and record an investigation of the pharmacology of 5-fluorocytosine, including laboratory studies on its activity in body fluids.
Clinical Ob,ervations
The patient, a married woman, aged 66 (weight 50 kg), had had chronic bladder outlet obstruction following the removal of a urethral caruncle 18 years previously. She had developed gross bilateral hydronephrosis and hydroureters with widely dilated urethral orifices. The bladder was trabeculated and showed multiple wide-mouth saccules. On admission with a further episode of retention her urine was found to be infected with a Staphylococcus aureus (105/ml) and C. albicans (104/ml). The presence of the fungus infection was confirmed in urine taken by suprapubic bladder puncture. The staphylococcal infection was eradicated by a course of cephaloridine but the candida infection persisted.
The presence of free ureteric reflux made upper urinary tract infection, with the risks of renal abscess formation and systemic infection, a strong possibility (Davis et al., 1956) . It was therefore considered necessary to give systemic therapy. A pre-existing impairment of renal function excluded the use of amphotericin B so 5-fluorocytosine was considered to be appropriate treatment. Treatment with 5-fluorocytosine was therefore given, initially in a dose of 2-5 g daily in divided doses for eight days but subsequently 5 g daily for a further 12 days. Twenty-four hour specimens of urine were collected for the estimation of 5-fluorocytosine concentration and excretion, and blood samples were taken for the estimation of 5-fluorocytosine serum levels.
The catheter was removed after nine days of treatment with 5-fluorocytosine but had to be reinserted for a further period when the patient developed another episode of urinary retention accompanied by a bacterial urinary infection and nitrogen retention; this infection was eradicated with a seven-day course of kanamycin. Two days later the patient developed a rash and joint pains which were attributed to one of the antimicrobial agents she had received. Shortly after this she also complained of some deafness, and the audiographic findings suggested this was due to an ototoxic drug, presumably the kananAycin.
Serum levels of 5-fluorocytosine after a single dose are shown in Fig. 1 , and the average levels during continuous therapy are shown in Fig. 2 , which also shows urinary concentration and total excretion of the drug. The haematological and biochemical results obtained by standard routine methods are shown in Table I . Treatment with 5-fluorocytosine (4 g daily) was begun and continued for 10 days. Though the urinary counts of candida were greatly reduced to 2 x 102/ml the infection persisted, and the drug was stopped when the patient was found to be slightly neutropenic (Fig. 3) . His white blood count later returned to normal and there was no evidence of thrombocytopenia on examination of blood smears. Blood and urine samples were taken for the estimation of 5-fluorocytosine and the results are shown in Table II .
The patient's renal function failed to recover and he eventually died four weeks after the course of 5-fluorocytosine finished. Necropsy was not undertaken.
Laboratory Investigations
Assay Procedure.-Assays were performed in glass assay trays 25 by 25 cm, the medium recommended by Shaddomy (1969) and the first patient's strain of C. albicans being used. (pg/ml) Tables III and IV. Serum Binding of 5-fluorocytosine.-A concentration of 100 ,ug/ml was prepared in serum without significantly diluting the proteins. After equilibration at 370C for two hours a 5 ml sample was centrifuged at 40,000 r.p.m. (mean g 125,000, temperature about 40C) for 21 hours. One millilitre of the supernatant was taken for comparison with a "100% free" standard solution of 5-fluorocytosine in buffer. In two separate assays protein binding of 5-fluorocytosine was calculated to be 48 and 49%. 
Discussion
In these two patients, both of whom suffered impaired renal function before therapy began, high urinary levels of 5-fluorocytosine were obtained, which supports the findings of Koechlin et al. (1966) that this drug is mainly excreted in the urine. The fact that serum levels in this study were higher than those recorded by Shaddomy (1969) may be attributed to the fact that both patients suffered from partial renal failure, which may account for the persistence of the drug in the urine and serum after the last dose. Similar concentrations of 5-fluorocytosine have been recorded in serum by Record et al. (1971) . No evidence of nephrotoxicity which might be attributed to the 5-fluorocytosine was observed. Though the drug was discontinued in Case 2 when the patient became marginally neutropenic, it cannot be concluded that this was the result of 5-fluorocytosine since his white blood cell count was variable before treatment. No platelet counts were undertaken. In this study, though serum binding was estimated at 48-49%, no loss of inhibitory activity due to binding was observed in the experiments described. On the contrary, in low concentrations the fungistatic effect of 5-fluorocytosine on T. glabrata and C. albicans was enhanced as investigated by the addition of serum to Wickerham's medium (Table IV) .
A number of workers, including Hendry and Bakerspigel (1969) (Table III ). Yet bioassay with C. albicans detected high levels of activity in diluted urine. It is possible that 5-fluorocytosine diffuses in agar at a different rate from the inhibitory substances which may occur in urine. Owing to the flushing of the bladder even a low level of fungistatic activity may suffice to eradicate infection in urinary candidiasis, and the first patient was undoubtedly cured of her urinary infection with C. albicans. After using 5-fluorocytosine therapy for 15 patients with cryptococcosis, Utz et al. (1968) concluded that it was a promising agent because it was relatively non-toxic and had the advantage of oral administration. Their views are supported by Warner et al. (1970) , who treated 10 patients with candidosis. Bennett (1970) , however, reported that bone marrow or liver toxicity was seen in 3 out of 16 patients with cryptococcosis and treated with from 4 to 6 g of 5-fluorocytosine daily. Webb et al., (1970) described a T. glabrata septicaemia treated with 5-fluorocytosine and recorded that no toxic effects were observed during a short course with moderate blood levels. In view of these findings, at the present time 5-fluorocytosine appears to be the drug of choice for urinary yeast infections.
Since Shaddomy (1969 and Utz et al. (1968) reported resistence to 5-fluorocytosine in isolates of Cryptococcus neoformans and C. albicans from patients receiving the drug, sensitivity studies should be undertaken before and during therapy. A single step acquisition of resistance may occur and further laboratory investigation is required.
